The Karl Harter Head and Neck Cancer Scholarship provides pilot research funds and support to students and fellows engaged in head and neck cancer research at the University of Wisconsin.
Karl Harter was diagnosed with Adenoid Cystic Carcinoma (ACC) in 1998 at the age of 47 with a complex tumor behind his right eye. He underwent craniofacial surgery followed by radiation and did beautifully for over 10 years. Tumor recurrence was noted in 2009 and he has since undergone several additional rounds of surgery and radiation. Karl never lost his passion for life through his 22-year fight with this rare form of cancer. He passed away in January 2020.
You can make a gift online to support the Karl Harter Head and Neck Cancer Scholarship.
“Cancer is a brutal disease. It has altered my life, but not my spirit. I have been scarred but not broken. My wife Christina says it took a village to keep me alive. The love and support of my wonderful family and friends has helped me prevail. The skill and expertise of the UW doctors, nurses and staff have been crucial. I feel lucky and amazingly grateful. I can never say thank you enough.
The Karl Harter Scholarship will fund research and innovation in the battle against head and neck cancer. But it will do much more by sending a message that cancer patients are not alone.
I still have cancer. Adenoid Cystic Carcinoma doesn’t quit, even 19 years later. But I am no quitter either. Nicked up maybe, but defeated, never. I have a village on my side.”
– Karl Harter
Adenoid Cystic Carcinoma
Donate to the Karl Harter Head and Neck Cancer Scholarship
Your support will help continue the tradition of excellence in teaching, research, and public service.Make a Gift
Adenoid Cystic Carcinoma (ACC) is a rare and challenging cancer that often originates in the head and neck region. ACC is slow growing but relentless, often characterized by progression many years after initial treatment. ACC can strike healthy individuals in the prime of life. Surgery and radiation are the cornerstones of current treatment. We are actively searching for successful chemotherapy drugs. New research efforts are critical to improve future outcomes.